In a man with metastatic colon cancer, administration of anti-IL-17 cleared psoriasis associated with pembrolizumab (anti-PD1) therapy but led to cancer progression, suggesting that IL-17 may have an antitumor effect (219). Here, IL17A is linked to psoriasis.